Rheumatoid Arthritis Drug May Prevent Lung Damage From COVID

October 25, 2021

A recent study has indicated that the autoimmune disease drug anakinra aided in the prevention of lung damage and death in mice infected with SARS-CoV-2.

Inflammatory lung vascular leakage can be presented in cases of severe COVID-19, when severe inflammation leads to the buildup of fluid in the lungs, and directly impacts the absorption of oxygen. It is estimated that 5-10% of patients develop acute respiratory distress syndrome (ARDS). “Hyperinflammation and cytokine storm are key pathogenic features underlying severe COVID-19 mediating ARDS and respiratory failure.” Mice in the study also showed signs of leakage from blood vessels in their lungs, as “analyses of postmortem lungs from COVID-19 patients and animal models show[ed] severe lung endothelial injury following the SARS-CoV-2 infection.”

The rheumatoid arthritis drug targets a specific molecular receptor that regulates inflammation, thereby suppressing a select immune pathway, versus suppressing the entire immune system. Mice who received the drug showed reduced signs of severe COVID-19, including less fluid buildup and less scarring of the lung tissue. Survival outcomes also increased. Researchers hypothesized that by assessing IL-1 receptor pathways, physicians may be able to detect when a patient’s immune system is about have a hyper response. The next step is conducting a clinical trial to investigate this drug in human participants experiencing severe COVID-19.





Join Our Community!Stay Informed. Stay Hopeful.

Sign up for periodic emails with resources, insights, and updates on autoimmune disease and living with chronic illness.

By adding your phone number, you agree to receive text message updates. Msg & data rates may apply.